Tampa, FL – August 15, 2008 -- Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that RTI Biologics, Inc., a global provider of sterile biological implants for surgeries, has selected Pilgrim’s integrated SmartAudit™, SmartCAPA™, and SmartComplaints™ modules to drive enterprise-wide productivity improvements and cost reductions.

In February 2008, Regeneration Technologies, Inc. merged with Tutogen Medical, Inc., forming RTI Biologics.  The transaction combined RTI’s expertise for science, safety and innovation in biologics for orthopedics with Tutogen’s leadership in sterile biologic implants for dental, hernia and other specialty surgeries. Following the merger, RTI had various manual and paper-based processes for corrective and preventive action, complaints and audit management and sought standardized processes for the entire organization. 

The company also was looking to implement stringent and automated audit and CAPA processes to maximize regulatory requirements and minimize risk and enable rapid responsiveness should any compliance or quality issues arise.

“We spent several months evaluating and comparing similar programs. The Pilgrim software modules seemed to have the best functionality, integration capability and work flows by far,” said Karen Norman, RTI’s Executive Director of Quality Assurance. “Although we have just begun our relationship with Pilgrim, the service has been excellent to date and we have high expectations going forward.”

“With a common workflow in place across all its sites and divisions, RTI Biologics looks to maintain ongoing management oversight into quality and compliance issues,” said Prashanth Rajendran, Pilgrim’s Chief Operating Officer.  With further improvements to its auditing, CAPA and complaints process efficiencies, the company should sustain a high level of customer satisfaction, further solidifying its reputation as a reliable provider.”

About RTI Biologics, Inc.
RTI Biologics, Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics—from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes, the BioCleanse® Tissue Sterilization Process and the Tutoplast® process, sterilize tissue, are clinically successful and are scientifically proven to eliminate donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of more than two million implants distributed with zero incidence of infection. In addition, RTI pastes are sterilized through the demineralization process, a validated viral inactivation step.

The company is leading the evolution of biologics once again by offering a bovine based biological matrix, providing surgeons an expanded supply of safe, sterile tissue for their patients.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks.

RTI Forward Looking Statement
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include but are not limited to statements about the expected benefits of the business combination involving RTI and Tutogen, including potential synergies and cost savings, future financial and operating results, and the combined company's plans and objectives.  In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results, regulatory approvals or changes to agreements with distributors also are forward-looking statements.  Forward-looking statements are subject to risks and uncertainties, including the ability of RTI to integrate its business successfully and to realize the expected synergies and cost savings from the merger and the risks described in public filings on file with the Securities and Exchange Commission (SEC).  Actual results may differ materially from anticipated results reflected in these forward-looking statements.  Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's Web site at www.rtix.com or the SEC's Web site at www.sec.gov.

About Pilgrim Software, Inc.   
Pilgrim Software, Inc. is a world-leading provider of Enterprise Compliance and Quality Management solutions for global organizations. Named 2007 & 2008 North American Enterprise Compliance & Quality Management Company of the Year by Frost & Sullivan, Pilgrim helps organizations manage industry and regulatory compliance, reduce manufacturing costs and improve customer satisfaction. For more information, visit Pilgrim Software’s website at www.pilgrimsoftware.com.